XT
TVRD

XTX Topco’s Tvardi Therapeutics TVRD Stock Holding History

XTX Topco’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,838
Closed -$55.2K – 4563
2025
Q4 		$55.2K Buy
+12,838
New +$115K ﹤0.01% 2804
2024
Q4 		– Sell
-2,631
Closed -$29.2K – 3067
2024
Q3 		$29.2K Buy
+2,631
New +$30.8K ﹤0.01% 1782
2024
Q2 		– Sell
-1,007
Closed -$33K – 2580
2024
Q1 		$33K Buy
1,007
+251
+33% +$6.51K ﹤0.01% 1538
2023
Q4 		$20.2K Buy
756
+251
+50% +$10.4K ﹤0.01% 1357
2023
Q3 		$30.5K Sell
505
-940
-65% -$88.2K 0.01% 1335
2023
Q2 		$147K Sell
1,445
-1,544
-52% -$213K 0.03% 1095
2023
Q1 		$528K Buy
2,989
+2,600
+668% +$871K 0.11% 261
2022
Q4 		$150K Buy
+389
New +$148K 0.03% 922

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

XTX Topco's TVRD Position: Q1 2026 in Review

XTX Topco sold out of Tvardi Therapeutics (TVRD) in Q1 2026, closing a stake of 12,838 shares — an estimated $55.2K sold.

XTX Topco first reported a position in TVRD in Q4 2022 and held it in 8 quarters. The position peaked at $528K in Q1 2023. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • XTX Topco reported no remaining Tvardi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • XTX Topco sold 12,838 Tvardi Therapeutics shares in Q1 2026, an estimated $55.2K.
  • XTX Topco first reported a position in Tvardi Therapeutics in Q4 2022 and held it in 8 quarters.
  • XTX Topco's Tvardi Therapeutics position peaked at $528K in Q1 2023.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.